Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

Abstract

OBJECTIVES\nTo develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).\n\n\nMATERIAL AND METHODS\nClinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively.\n\n\nRESULTS\nThe OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c\xa0=\xa00.66, c\xa0=\xa00.66 and c\xa0=\xa00.73, respectively. External validation of these nomograms yielded c\xa0=\xa00.59, c\xa0=\xa00.70, and c\xa0=\xa00.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome.\n\n\nCONCLUSIONS\nWe have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.